​

Funding Round

Series B - HI-Bio

Series B - HI-Bio

Investment Firm

Overview

Human Immunology Biosciences is a biotechnology company that focuses on developing therapies for immune-mediated diseases.

Announced Date

Jan 04, 2024

Closed on Date

Jan 04, 2024

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Alpha Wave Global

Alpha Wave Global

Alpha Wave Global is a convertible_note and debt and early_stage_venture and late_stage_venture and private_equity and seed and venture firm.

Participant Investors

5

Investor Name
Participant InvestorAlpha Wave Global
Participant InvestorArkin Holdings
Participant InvestorViking Global Investors
Participant InvestorJeito Capital
Participant InvestorARCH Venture Partners

Round Details and Background

HI-Bio raised $95000000 on 2024-01-04 in Series B

Human Immunology Biosciences is a biotechnology company that focuses on developing therapies for immune-mediated diseases.

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Nov 01, 2022
Series A - HI-Bio
4-120.0M
Jan 04, 2024
Series B - HI-Bio
5-95.0M

Recent Activity

There is no recent news or activity for this profile.